about
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsEarly-Stage Breast Cancer in the Elderly: Confronting an Old Clinical ProblemNuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studyCurrent breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases.Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expressionApplication of intraoperative frozen section examination in the management of female breast cancer in China: a nationwide, multicenter 10-year epidemiological studyPost-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.Clinicopathologic characteristics of typical medullary breast carcinoma: a retrospective study of 117 cases.Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysisDownregulation of serine protease HTRA1 is associated with poor survival in breast cancerTamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivorsOptimal systemic therapy for early breast cancer in women: a clinical practice guidelineOne-Step Nucleic Acid Amplification in Breast Cancer Sentinel Lymph Node: A Single Institutional Experience and a Short Review.Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer ConsortiumManaging arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study.Prognostic molecular assays on the rise for non-small cell lung cancer.ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factorA dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysisKi-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryDevelopment and clinical application of an integrative genomic approach to personalized cancer therapyMolecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.Role of postmastectomy radiation therapy in breast cancer patients with T1-2 and 1-3 positive lymph nodes.Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.Initialization of adjuvant hormonal treatment for breast cancer.A current update on osteonecrosis of the jaw and bisphosphonates.Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review.The changing role of axillary lymph node dissection for breast cancer.
P2860
Q26782449-9850801F-6E1B-46C5-BC79-27ADC9055293Q26782584-16C7EDFE-FFDE-4323-8EBC-1F378BDCE94EQ30009589-45F02A92-9F04-481C-9E72-A3674AB602B8Q33551425-2DFC7520-EEF7-439F-B3A4-CCA3012E435CQ33687123-EDD0C73A-1ECF-45C6-AC64-8A38869345E4Q33751806-70899863-E3F9-4551-9F26-65A79B5E5677Q33800620-3DA68ADE-84C5-4807-9468-8690F2702162Q33927640-4D3133CB-81A4-46FE-A791-9DE665CAC809Q33946372-F6641033-941D-49C8-9685-A80DCFDB922DQ34130140-5748DAFB-3C47-4211-8673-BC7C8B303DE7Q34196301-9A3275A0-0000-4183-AA24-1FBC9D45928CQ34454213-3EAC24C6-CB81-4CE8-A458-B6ADA3A523DCQ34465749-7A042C0E-C46A-4260-93CE-9DABF7AB4598Q34501893-9B0353E7-D529-4455-BF70-85796F9407D3Q34666305-DFF6695F-BF6A-4E2B-A604-CD9B948B17EFQ35020403-5861E687-FAA9-4E83-BF50-363243D1A641Q35211629-548214A6-4E82-46B7-9BC5-B45FC73234DAQ35215032-580FEF53-779C-4478-A3D0-753A1AFC30B1Q35239634-B3568412-C900-47EC-AFC9-F1EEAA7BE929Q35747268-3525DC51-8BA9-4885-8D49-CB2735D957CDQ35913234-2003F5F4-6FC6-4D9B-B115-3E6A7BD06674Q35915758-8CDFBC1F-27C1-4070-990B-44A6F6D62E12Q35938880-7F392310-192C-40BA-BE26-0B600D49FFD1Q36042370-D0246681-3FBC-466D-BAA3-A16E763BE9BDQ36198154-C4CFDC1A-BA3F-4B53-AAB5-733B59095367Q36339076-B24B25EE-D427-4A18-853F-7836573DF262Q36740827-2C05C360-F322-4DBA-B4E2-42E601C030D7Q36759043-FA3CBFE3-7A96-4ABE-994E-0435BC863C56Q36762888-52BCADA3-5061-4E99-8CFE-E99BAE69AAF7Q36892788-C5EBE118-4F71-4B58-BDA4-D94FCF10FAB0Q36954557-E5F73442-CEE7-41E3-B03D-89335975E265Q37094017-A9A27E4D-EA1B-414B-B252-B00D2819EAC6Q37161492-2A131E0C-47E0-40FB-ADF7-777E2B91A270Q37258915-896742E2-11F8-4903-A8D1-31250089920FQ37583113-6FA57799-C857-42D2-A748-56991506B81CQ37921641-4532D59D-6ED6-4663-A745-4FA8933806F0Q37933168-C5535CF1-63E6-4877-ACA7-C79E28A5B001Q37992647-CE2AB33F-FA91-40D5-A634-F8132F292A2BQ38048818-A839038E-5FE6-40D9-88F7-C3AD6D79107AQ38051233-85D63A24-E809-4A05-A8A0-B1B2672B8639
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
St. Gallen 2011: Summary of the Consensus Discussion.
@ast
St. Gallen 2011: Summary of the Consensus Discussion.
@en
St. Gallen 2011: Summary of the Consensus Discussion.
@nl
type
label
St. Gallen 2011: Summary of the Consensus Discussion.
@ast
St. Gallen 2011: Summary of the Consensus Discussion.
@en
St. Gallen 2011: Summary of the Consensus Discussion.
@nl
prefLabel
St. Gallen 2011: Summary of the Consensus Discussion.
@ast
St. Gallen 2011: Summary of the Consensus Discussion.
@en
St. Gallen 2011: Summary of the Consensus Discussion.
@nl
P2860
P356
P1433
P1476
St. Gallen 2011: Summary of the Consensus Discussion.
@en
P2093
Christoph Thomssen
P2860
P304
P356
10.1159/000328054
P577
2011-04-29T00:00:00Z